Home » Stocks » Haemonetics

Haemonetics Corporation (HAE)

Stock Price: $87.20 USD -0.46 (-0.52%)
Updated Aug 3, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 4.39B
Revenue (ttm) 988.48M
Net Income (ttm) 76.53M
Shares Out 50.39M
EPS (ttm) 1.48
PE Ratio 58.92
Forward PE 33.11
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 3, 2020
Last Price $87.20
Previous Close $87.66
Change ($) -0.46
Change (%) -0.52%
Day's Open 88.08
Day's Range 86.99 - 89.03
Day's Volume 552,556
52-Week Range 63.41 - 140.36

More Stats

Market Cap 4.39B
Enterprise Value 4.64B
Earnings Date (est) Aug 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 50.39M
Float 49.93M
EPS (basic) 1.51
EPS (diluted) 1.48
FCF / Share 2.49
Dividend n/a
Dividend Yield n/a
Earnings Yield 1.70%
FCF Yield 2.87%
Payout Ratio n/a
Shares Short 792,050
Short Ratio 0.86
Short % of Float 2.04%
Beta 0.68
PE Ratio 58.92
Forward PE 33.11
P/FCF Ratio 34.81
PS Ratio 4.44
PB Ratio 7.57
Revenue 988.48M
Operating Income 103.35M
Net Income 76.53M
Free Cash Flow 126.23M
Net Cash -245.18M
Net Cash / Share -4.87
Gross Margin 49.35%
Operating Margin 10.46%
Profit Margin 7.70%
FCF Margin 12.77%
ROA 8.55%
ROE 12.20%
ROIC 11.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 5
Overweight 1
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$130.33*
(49.46% upside)
Low
110
Current: $87.20
High
165
Target: 130.33
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172017201620142013201220112011
Revenue988968904886909910939892728677
Revenue Growth2.16%7.04%2.01%-2.5%-0.17%-3%5.22%22.55%7.56%-
Gross Profit485418412378406434468428369355
Operating Income10383.5556.16-19.38-43.9440.5446.4356.4488.76111
Net Income76.5355.0245.57-26.27-55.5816.9035.1538.8066.8979.98
Shares Outstanding50.6951.5352.7651.5250.9151.5351.6151.3550.7350.15
Earnings Per Share1.481.040.85-0.51-1.090.320.670.741.301.56
EPS Growth42.31%22.35%----52.24%-9.46%-43.08%-16.67%-
Operating Cash Flow15815922016012212714085.07115123
Capital Expenditures-31.98-116-72.04-73.31-102-122-73.16-60.22-52.20-45.20
Free Cash Flow12643.1314886.4320.105.4166.3624.8563.1278.25
Cash & Equivalents137169180140115161192179229197
Total Debt3823502543154084284384803.774.88
Net Cash / Debt-245-181-73.51-175-293-267-245-301225192
Assets1,2671,2751,2371,2391,3191,4851,5141,462911833
Liabilities680607485499598659676693179147
Book Value587668752740722826838769733686
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Haemonetics Corporation
Country United States
Employees 3,004
CEO Christopher A. Simon

Stock Information

Ticker Symbol HAE
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Medical Instruments & Supplies
Unique Identifier NYSE: HAE
IPO Date May 9, 1991

Description

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.